CA3293959A1 - Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases - Google Patents
Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseasesInfo
- Publication number
- CA3293959A1 CA3293959A1 CA3293959A CA3293959A CA3293959A1 CA 3293959 A1 CA3293959 A1 CA 3293959A1 CA 3293959 A CA3293959 A CA 3293959A CA 3293959 A CA3293959 A CA 3293959A CA 3293959 A1 CA3293959 A1 CA 3293959A1
- Authority
- CA
- Canada
- Prior art keywords
- sub
- math
- sup
- semantics
- annotation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3293959A CA3293959A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/055770 WO2021071499A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
| CA3293959A CA3293959A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
| CA3154392A CA3154392C (en) | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3154392A Division CA3154392C (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3293959A1 true CA3293959A1 (en) | 2026-03-02 |
Family
ID=68387423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3293959A Pending CA3293959A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11779597B2 (enExample) |
| EP (1) | EP4041214A1 (enExample) |
| JP (4) | JP7634895B2 (enExample) |
| AU (1) | AU2019470001B2 (enExample) |
| CA (1) | CA3293959A1 (enExample) |
| WO (1) | WO2021071499A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116077524A (zh) * | 2023-02-27 | 2023-05-09 | 广西馨海药业科技有限公司 | 氯化铷在制备治疗帕金森综合征的药物中的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE167473T1 (de) | 1990-08-20 | 1998-07-15 | Eisai Co Ltd | Sulfonamid-derivate |
| JP2790926B2 (ja) * | 1990-08-20 | 1998-08-27 | エーザイ株式会社 | スルホンアミド誘導体 |
| US6162350A (en) | 1997-07-15 | 2000-12-19 | Exxon Research And Engineering Company | Hydroprocessing using bulk Group VIII/Group VIB catalysts (HEN-9901) |
| WO2015185602A1 (en) * | 2014-06-04 | 2015-12-10 | Affiris Ag | Treatment and prevention of parkinson's disease (pd) |
| US20160153957A1 (en) | 2014-12-01 | 2016-06-02 | Peter Y. Novak | Method for diagnostics of pathology in biologocal objects |
| US10226484B2 (en) | 2014-12-01 | 2019-03-12 | Peter Y Novak | Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof |
| MX2018009662A (es) * | 2016-02-11 | 2018-09-11 | Chevion Mordechai | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. |
| CN106581056A (zh) * | 2016-10-11 | 2017-04-26 | 徐志强 | 锌在制造治疗帕金森病药物的用途 |
| US10183041B2 (en) | 2017-04-12 | 2019-01-22 | Vector Vitale Ip Llc | Antibacterial composition and its use in treating bacterial infections |
| US10933091B1 (en) | 2019-12-20 | 2021-03-02 | Vector Vitale Ip Llc | Composition and method for the treatment of type I diabetes |
| US10799530B1 (en) | 2019-12-20 | 2020-10-13 | Vector Vitale Ip Llc | Composition and method for the prevention and treatment of obesity |
-
2019
- 2019-10-11 US US17/768,190 patent/US11779597B2/en active Active
- 2019-10-11 AU AU2019470001A patent/AU2019470001B2/en active Active
- 2019-10-11 EP EP19795409.2A patent/EP4041214A1/en active Pending
- 2019-10-11 JP JP2022522035A patent/JP7634895B2/ja active Active
- 2019-10-11 WO PCT/US2019/055770 patent/WO2021071499A1/en not_active Ceased
- 2019-10-11 CA CA3293959A patent/CA3293959A1/en active Pending
-
2023
- 2023-08-28 US US18/238,817 patent/US12036238B2/en active Active
-
2024
- 2024-01-05 JP JP2024000684A patent/JP2024038270A/ja not_active Withdrawn
-
2025
- 2025-07-04 JP JP2025113738A patent/JP2025148408A/ja active Pending
- 2025-11-25 JP JP2025202951A patent/JP2026035686A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4041214A1 (en) | 2022-08-17 |
| JP2022551943A (ja) | 2022-12-14 |
| JP2025148408A (ja) | 2025-10-07 |
| US12036238B2 (en) | 2024-07-16 |
| AU2019470001A1 (en) | 2022-05-12 |
| CA3154392A1 (en) | 2021-04-15 |
| US20240173350A1 (en) | 2024-05-30 |
| AU2019470001B2 (en) | 2024-09-19 |
| JP2024038270A (ja) | 2024-03-19 |
| US11779597B2 (en) | 2023-10-10 |
| JP7634895B2 (ja) | 2025-02-25 |
| WO2021071499A1 (en) | 2021-04-15 |
| NZ787735A (en) | 2025-03-28 |
| JP2026035686A (ja) | 2026-03-04 |
| US20230210894A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Andrabi et al. | Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti‐apoptotic effects of melatonin | |
| JP5736421B2 (ja) | 生理学的過程の調節およびこれに有用な薬剤 | |
| ES2685947T3 (es) | Agentes antienvejecimiento | |
| Guo et al. | Anti-fibrotic effects of puerarin on CCl4-induced hepatic fibrosis in rats possibly through the regulation of PPAR-γ expression and inhibition of PI3K/Akt pathway | |
| US7223554B2 (en) | Inhibitors of proteasomal activity for stimulating hair growth | |
| JP2018021033A (ja) | ペプチド治療薬およびその使用方法 | |
| US6174875B1 (en) | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke | |
| US20060167106A1 (en) | Compounds acting at the centrosome | |
| Lim et al. | Development of metabolic and contractile alterations in development of cancer cachexia in female tumor-bearing mice | |
| CN115645388A (zh) | 氨基酸组合物及其用途 | |
| Saadi et al. | Spatial, temporal, and cell-type-specific expression of NADPH Oxidase isoforms following seizure models in rats | |
| JP2026035686A (ja) | パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物 | |
| Shen et al. | SIRT3-mediated deacetylation of SDHA rescues mitochondrial bioenergetics contributing to neuroprotection in rotenone-induced PD models | |
| Ren et al. | Upregulation of thioredoxin contributes to inhibiting diabetic hearing impairment | |
| Samin et al. | Acetyl-L-carnitine protects against LPS induced depression via PPAR-γ induced inhibition of NF-κB/NLRP3 pathway | |
| WO1999051223A1 (en) | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke | |
| US12383554B2 (en) | Compositions and methods to protect mammalian tissue against cold and other metabolic stresses | |
| US20210000877A1 (en) | Method For Upregulation Of Thioredoxin Expression In Stem Cells | |
| Wang et al. | Activation of SIRT3 alleviates neurodegeneration via rescuing mitochondrial succinate dehydrogenase activity and bioenergy supply in rotenone-induced PD models | |
| JP2010539242A (ja) | サルコシンレベルを増大させる方法 | |
| TWI722492B (zh) | 含蓮蓬萃取物之組合物及其用於治療頭頸癌症之用途 | |
| AU2023463679A1 (en) | New use of a pde 5 inhibitor combination in promoting neurite outgrowth | |
| EA048019B1 (ru) | Синтетические нейромодулирующие пептиды | |
| Isaacs | The effect of melatonin treatment on doxorubicin-induced skeletal muscle atrophy within a cancer model | |
| Abounit | The process of autophagy in an in vitro model of myocardial ischemia-reperfusion injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL Effective date: 20251128 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251128 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251128 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20251231 |
|
| A18 | Application divided or continuation or continuation in part accepted |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251231 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251231 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251231 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260108 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260128 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20260128 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-2-2-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION) Effective date: 20260302 |